A. Yokomizo

Publications20
h-index10
Citations339
Highly Influential Citations7
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Kuwano
  • 564 Publications • 24,388 Citations
  • K. Kohno
  • 297 Publications • 12,668 Citations
  • S. Naito
  • 627 Publications • 11,516 Citations
  • M. Wada
  • 39 Publications • 707 Citations
  • Publications
  • Influence
Mechanisms of drug resistance in chemotherapy for urogenital carcinoma
Cancer chemotherapy is the principal approach for urogenital cancers. However, the acquisition of resistance to anticancer agents is a critical factor that limits the successful treatment of… Expand
  • 47
  • 4
Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
We established three cis-diamminedichloroplatinum(II) (cisplatin)-resistant cell lines, T24/DDP5, T24/DDP7, and T24/DDP10, by the stepwise exposure of T24 human bladder cancer cells to increasing… Expand
  • 71
  • 2
  • PDF
Hand assisted laparoscopic radical nephrectomy for renal carcinoma using a new abdominal wall sealing device.
PURPOSE We report our initial experience with a hand assisted laparoscopic radical nephrectomy for patients with renal carcinoma, and compare our results to those of conventional open radical… Expand
  • 35
  • 1
Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype.
PURPOSE To elucidate the mechanisms of cisplatin resistance in human bladder cancer. MATERIALS AND METHODS After continuous exposure of KK47 cells to cisplatin, two resistant sublines, KK47/DDP10… Expand
  • 34
Impact of reporting rules of biopsy Gleason score for prostate cancer
Aims: To investigate how the biopsy Gleason score (GS) and the clinical risk classification have been changed by the reporting rules. Methods: 565 prostate biopsy specimens were reassessed. Each… Expand
  • 25
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: exploration of 5-6 fused rings as alternative S1 moieties.
A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5-6 fused rings as alternative S1… Expand
  • 38
Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and…
In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a having two amidino groups. However, it had poor oral bioavailability due to its strong basic amidino groups. To… Expand
  • 27
Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: novel, highly potent and orally efficacious squalene synthase inhibitors.
We have recently reported the discovery of the new benzhydrol template, which has a highly potent inhibitory activity for squalene synthase, as typified by compound 1 (SSI IC(50)=0.85 nM). However,… Expand
  • 16
Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines.
We investigated the mechanism of intrinsic resistance to cisplatin in human transitional cell cancer (TCC) using 7 human bladder cancer cell lines, which were derived from untreated TCC of the… Expand
  • 16
Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors.
To obtain small and efficient squalene synthase inhibitors, a flexible 2-aminobenzhydrol open form structure was designed and showed potent inhibitory activity comparable to 4,1-benzoxazepin… Expand
  • 13
...
1
2
...